and improved convalescence. The surgeon's skill in laparoscopic technique, appropriate patient selection, and the ability to adhere to oncologic principles, including complete excision without tumor spillage, are of utmost importance when deciding the appropriate surgical intervention.
The adrenal gland is a common site of metastasis and can be afflicted by malignancies from a multitude of primary sites. [1] [2] [3] The rich sinusoidal blood flow and multiple pathways of arterial blood supply may contribute to the high incidence of metastatic implantation. 1, 3 In one autopsy review of 1,000 patients with malignancy, metastases to the adrenal glands were found in 27% of patients. 2 The most common sites metastasizing to the adrenal glands are breast, lung, gastrointestinal tract, skin (melanomas), and kidney. Lung and breast cancers have been found to account for approximately 39% and 35% of adrenal metastases, respectively, and adrenal metastases can be seen in up to 40% to 50% of patients with melanomas and liver or renal cell cancers. [2] [3] [4] Patients with adrenal metastasis are typically asymptomatic but can uncommonly present with back pain, retroperitoneal hemorrhage, or adrenal insufficiency. 1, 5 In one study, symptomatic metastases were larger in size when compared to asymptomatic lesions and also were associated with a significantly younger patient population. 5 Overwhelmingly, however, the majority of adrenal metastases are either discovered incidentally during the staging workup for a primary malignancy or identified on repeat radiological studies for surveillance after initial treatment. Over a 30-year period, Lam and Lo found that adrenal metastases were most frequently discovered within a relatively brief period of time after detection of the primary malignancy (median latent period, 7 months), with less than 2% of cases having metastases to the adrenals more than 5 years after diagnosis. 5 Imaging Improvements in imaging techniques have allowed the ready detection and characterization of adrenal gland metastases. [6] [7] [8] [9] [10] [11] [12] Computed tomography (CT) with and without oral and intravenous iodinated contrast is useful in assessing adrenal lesions. Oral contrast should be given to distinguish the adrenal glands from surrounding organs. On CT, metastatic lesions are generally nonspecific and can have a wide array of radiographic features. The size can vary from less than a centimeter to a large mass. They may have a discrete focus or be multifocal; they can be smooth, irregular, or have a lobulated contour. Lesions can be unilateral or bilateral, can show evidence of local invasion, and may be associated with hemorrhage. Calcifications are a rare finding in metastatic lesions, but necrosis may be present. Intracellular lipid content and vascular enhancement are two CT criteria that can be useful in differentiating benign adenomas from malignant adrenal masses. 6 Metastatic lesions typically have low levels of intracytoplasmic fat in the adrenal cortex as compared to adenomas (70% of cases) and will have lower attenuation than adenomas on noncontrast CT. 6, 7, 10, 11 After the administration of iodinated contrast there is usually a more obvious heterogeneous enhancement pattern compared to adenomas and a significantly delayed contrast material washout. 6, 7, 9 Magnetic resonance imaging (MRI) is another useful tool for evaluating metastatic lesions to the adrenal glands. MRI can be used in patients who have a contraindication to intravenous contrast, particularly those with an iodine allergy or those in renal insufficiency. T1-weighted magnetic resonance images of metastatic tumors have a signal intensity that is similar to adrenal adenomas and may be confused with benign lesions. 6, 7 On T2-weighted imaging, lesions are likely to be heterogeneous and hyper-intense when compared to liver. T2-weighted imaging with opposed-phase imaging (in and out of phase) will show no decrease in intensity secondary to the decreased lipid content in the mass. After the administration of intravenous gadoliniumcomplex, most tumors are hyper-intense and show heterogeneous enhancement. Using T2-weighted fat-suppressed images, MRI may distinguish between normal and neoplastic tissue. 7 Ultrasonography may detect adrenal lesions that are larger than 2 cm. However, ultrasound has not been as useful as CT in the evaluation of metastatic adrenal lesions. 13, 14 The sensitivity and specificity for ultrasound were found to be 79% and 61%, respectively, as compared to 84% and 98% for CT. 13 Operator experience, body habitus, bowel gas, and lack of specific imaging patterns are all impeding factors. Preliminary results with positron emission tomography (PET) have shown some promise in differentiating malignant lesions using 18-fluorodeoxyglucose, but further studies are needed to better define the role of this technology in assessing adrenal lesions. 6 
Clinical and Serological Diagnosis
Establishing a diagnosis of metastatic disease versus benign disease is paramount. As discussed, metastatic lesions can have nonspecific findings on imaging and thus can overlap with benign adrenal masses in size and radiological detail. Patients should be questioned for signs and symptoms of a metabolically active primary adrenal tumor, such as hypertension, tachycardia, headache, palpitations, hirsutism, or change in body habitus. A physical examination should be performed looking for the stigmata of the other etiologies of adrenal pathology, including examination for lymphadenopathy, thyroid lesions, and genitourinary abnormalities. Serum electrolytes, as well as urine and serum analysis for aldosterone, cortisol, sex hormone steroids, and catecholamines and their metabolites such as metanephric acid, should be performed to evaluate for primary adrenal tumors. 15, 16 Biopsy Fine-needle aspiration (FNA) with CT guidance can be performed safely and is highly sensitive and specific for diagnosing adrenal metastasis. 17, 18 FNA also is useful for defining a primary malignancy of unknown origin. The accuracy of FNA has improved with advances in immunocytochemistry techniques, which have a specificity and sensitivity reported to be as high as 85% to 94% and 100%, respectively. 17 Several series confirm that surgical management of a metastatic adrenal lesion does improve survival in select patients and can lead to potential cure. 19, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] In a series reported by Higashiyama et al, lung cancer patients with isolated metastatic disease to the adrenal gland who underwent surgical resection followed by adjuvant chemotherapy or radiotherapy fared much better than patients treated non-operatively. 27 This study demonstrated a median survival of less than 6 months for patients treated medically, and survival benefit of greater than 9 months in the surgical group, with one patient showing no disease progression after 40 months. Luketich and Burt found a 3-year actuarial survival of 38% in solitary adrenal metastatic lesions from non-small cell lung cancer managed with chemotherapy followed by adrenalectomy compared with chemotherapy alone. 26 The survival in the surgery group was significantly improved with a median of 31 months, versus 8.5 months, and all of the patients in the chemotherapy group without surgery died within 22 months. 26 Several studies have tried to identify patients who may benefit from surgical excision of metastatic adrenal lesions. Adrenalectomy has been found to be most beneficial when the primary cancer is controllable and when there is no evidence of extra-adrenal metastases. 30 Siemer et al examined renal cell cancer patients and noted that patients with a solitary adrenal metastasis achieved a significant tumor-specific survival benefit with a median survival of 68 months compared to a median survival of 10 months in those patients with additional metastatic foci. 25 Risk factors such as the site of the primary cancer, size, histology, primary tumor type (adenocarcinoma possibly being more favorable), presence of other distant metastases, local invasion, and a lengthy disease-free interval after initial diagnosis appear to impact on cancer survival, but these risk factors have been somewhat variable. 4, [25] [26] [27] [28] [29] [30] [31] [32] [33] The optimal surgical approach for adrenalectomy for metastatic (median survival, 21 months). 29 They found that complete resection and a disease-free interval of greater than 6 months were predictors of survival.
Advocates of open adrenalectomy voice many concerns with laparoscopy, such as the possibility of tumor seeding and subsequent carcinomatosis due to carbon dioxide insufflation, violation of the adrenal gland and tumor spillage, the possible immunosuppressive affects of the pneumoperitoneum, and potential port site metastasis as reasons to avoid laparoscopic surgery. 28, 30, 34, 35 Additionally, Kebebew et al demonstrated that inadvertent laparoscopic resection of clinically unsuspected adrenocortical carcinoma exhibited a high local recurrence rate. 19 Gerber et al reported on their experience with laparoscopic adrenalectomy for lung cancer patients with a solitary metastasis to the adrenal gland. 36 They found that these patients had an inflammatory reaction that made dissection during laparascopy more difficult than with benign disease to the adrenal gland, and concluded that lesions greater than 5 cm are less amenable to laparoscopic adrenalectomy and have a higher rate of open conversion.
The incidence of port site metastasis has been estimated to be from 0% to 6.25%. 35 Causes of port site metastasis can be grouped into several categories: tumor aggressiveness (type of tumor and its natural behavior), local wound factors (implanting in the early stages of wound healing, tumor cell adherence to wound margins, and release of growth factors), host immune response, and laparoscopy-related factors (ie, type of gas used for insufflation, surgical manipulation, tumor spillage). 35 In their review of the urologic literature, Tsvian et al found nine cases of port site metastasis. The putative causative factors of port site metastasis were high stage or grade primary tumor, violation of tumor boundaries, intracorporeal morcellation of the tumor specimen, and disuse of an entrapment bag during specimen retrieval. Other potential risk factors were pre-existing immunosuppression and the presence of ascites. 35, 37 There have been contradictory reports on the role of the pneumoperitoneum as the cause of port site metastasis and carcinomatosis. [38] [39] [40] In an novel study by Ikramuddin et al, carbon dioxide effluent recovered from patients with cancer during laparoscopy was examined. 40 The authors concluded that malignant cells are aerosolized in laparoscopic surgery, but in patients without carcinomatosis, aerosolization is unlikely to contribute to port site metastasis. and small organ-confined adrenal masses were best suited for a laparoscopic procedure. Specific contraindications to laparoscopic adrenalectomy were irregular adrenal masses with peri-adrenal infiltration into adjacent organs. The authors suggested that a laparoscopic approach should be abandoned if there are concerns regarding the adequacy of wide excision, and care should be taken not to violate the adrenal mass, to avoid tumor spillage, and to remove the specimen intact rather than through morcellation, with the use of a laparoscopic bag to withdraw the specimen.
Alternative approaches to the treatment of metastatic disease to the adrenal gland have been examined. 43, 44, 46, 47 Percutaneous radiofrequency ablation (RFA) has exhibited some promise in treating malignant adrenal tumors. 43, 44 RFA utilizes alternating radiofrequencies, which generate heat and lead to tissue necrosis and destruction. In a preliminary study of RFA of metastatic adrenal lesions, tumor recurrence occurred in two of 11 patients after RFA treatment. 43 Percutaneous ethanol ablation is another non-invasive approach that has been investigated for adrenal tumors.
Ethanol is cytotoxic and thrombogenic and has shown promise in shortterm studies. 46, 47 Although the specific roles for RFA and ethanol ablation have not been established and long-term data are still pending, these percutaneous techniques may have promise for patients who are nonoperative candidates or those who refuse surgical intervention.
Conclusion
The surgical management of adrenal metastatic lesions has shown benefit in the survival of select patients with a variety of primary tumors.
Adrenal metastesectomy also has exhibited success when used as an adjunct to chemotherapy, and has been found to be more successful than chemotherapy and radiation alone. Controversy remains over the use of laparoscopic adrenalectomy, although in a number of studies there seems to be at least a parallel survival benefit when compared to open adrenalectomy, with improved convalescence. The importance of patient selection, surgeon comfort level and experience, adequate surgical planning, and adherence to oncologic principles cannot be overstated when performing laparoscopic adrenalectomy for metastastic lesions.
